Several clinical studies in patients with mCRC have noted a relationship between the concentration of symptoms such as hypertension, biomarkers (e.g., lactate dehydrogenase, ICAM, E-selectin, endothelial nitric oxide synthase) and the SNPs of genes involved in the angiogenesis pathway and the response to bevacizumab [20,21,22,23,24,25,26]. This evidence concerns the gene NOS3 and Hypertension.